Less than 10% of people who could benefit from weight-loss injections including Wegovy have access to them, states the WHO as it publishes its inaugural advice on the medications.
With more than one billion individuals worldwide currently obese, it is advocating for increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidelines affirms that obesity is a lifelong illness that can be managed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major obstacles to widespread access to the treatments that can aid individuals in losing significant weight, explains the body.
Skinny Jab Supply Crisis
Despite the current most optimistic outlook, the production of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, as stated by the WHO.
The recommendation urges governments and firms to expand access, through measures including voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
How Weight-Loss Jabs Function
These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals eat less.
Individuals usually see weight reduction after several weeks of beginning the weekly injections.
Research points to people may see weight return a year later of halting the treatment, as their typical food cravings return.
Being carrying excess weight elevates your risk for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Obesity affects people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, per the WHO.
